日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

[A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide]

[采用临床算法的个性化、循证肥胖治疗方法：索玛鲁肽或替拉帕肽]

期刊:
影响因子:
doi:10.14341/probl13677
Troshina, E A; Antsiferov, M B; Ametov, A S; Galstyan, G R; Markova, T N; Romantsova, T I; Mazurina, N V; Koteshkova, O M
肥胖
代谢
发表日期：2025
文献求助 收藏

A New Approach to Overcome Insulin Resistance in Patients with Impaired Glucose Tolerance: The Results of a Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety of Subetta

克服糖耐量受损患者胰岛素抵抗的新方法：一项多中心、双盲、安慰剂对照、随机临床试验评估Subetta疗效和安全性的结果

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm11051390
Mkrtumyan, Ashot; Ametov, Alexander; Demidova, Tatiana; Volkova, Anna; Dudinskaya, Ekaterina; Vertkin, Arkady; Vorobiev, Sergei
代谢
免疫/内分泌
发表日期：2022
文献求助 收藏

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

全球范围内，对于高危2型糖尿病患者使用具有心肾保护作用的降血糖药物（SGLT2抑制剂和GLP-1受体激动剂）仍存在惰性。

期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-020-01154-w
Schernthaner, Guntram; Shehadeh, Naim; Ametov, Alexander S; Bazarova, Anna V; Ebrahimi, Fahim; Fasching, Peter; Janež, Andrej; Kempler, Péter; Konrāde, Ilze; Lalić, Nebojša M; Mankovsky, Boris; Martinka, Emil; Rahelić, Dario; Serafinceanu, Cristian; Škrha, Jan; Tankova, Tsvetalina; Visockienė, Žydrūnė
SGLT2
GLP-1
信号转导
代谢
糖尿病
发表日期：2020
文献求助 收藏

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

来自常规临床实践的证据：EMPRISE 为心血管结局试验 (CVOT) 提供了新的视角

期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-019-0920-3
Schernthaner, Guntram; Karasik, Avraham; Abraitienė, Agnė; Ametov, Alexander S; Gaàl, Zsolt; Gumprecht, Janusz; Janež, Andrej; Kaser, Susanne; Lalić, Katarina; Mankovsky, Boris N; Moshkovich, Evgeny; Past, Marju; Prázný, Martin; Radulian, Gabriela; Smirčić Duvnjak, Lea; Tkáč, Ivan; Trušinskis, Kārlis
发表日期：2019
文献求助 收藏